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Abstract
Left ventricular noncompaction (LVNC) is an uncommon cardiomyopathy characterized by
the persistence of fetal myocardium with a pattern of prominent trabecular meshwork and deep
intertrabecular recesses, systolic dysfunction and left ventricular dilatation. It is thought to be
caused by the arrest of normal endomyocardial morphogenesis. There is no consensus on the
definition, diagnostic criteria, pathogenesis or treatment of LVNC. We report the case of
a 43 year-old patient with LVNC, nonsustained ventricular tachycardia and family history of
sudden cardiac death (SCD). An implantable cardioverter-defibrillator (ICD) was prophyla-
ctically implanted because of the individual’s high SCD risk. Although ICD is an effective
option for preventing SCD, data on the long-term follow-up of patients with LVNC is limited.
(Cardiol J 2011; 18, 6: 691–694)
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Introduction
Left ventricular noncompaction (LVNC), first
described in 1990, is an uncommon cardiomyopa-
thy characterized by the persistence of fetal myo-
cardium with excessive prominence of trabecular
meshwork and deep intertrabecular recesses,
systolic dysfunction and left ventricular (LV) dila-
tation [1]. With a prevalence of 0.014%, men are
more affected than women [2]. Although LVNC has
been classified as a primary cardiomyopathy of ge-
netic origin, its definition, diagnostic criteria and
treatment modalities are still being debated. It has
been suggested that it is caused by an arrest of the
normal process of intrauterine endomyocardial and
myocardial morphogenesis [1]. Clinical manifesta-
tions are highly variable, ranging from no symptoms
to a progressive deterioration in cardiac function
that results in congestive heart failure, systemic
thromboemboli, arrhythmias, and sudden cardiac
death (SCD) [3, 4]. Outcomes and appropriate thera-
pies remain poorly defined. Pharmacological treat-
ment and implantable cardioverter-defibrillators
(ICD) may be considered for the management of
ventricular arrhythmias (VA) in patients with this
cardiomyopathy. The prognosis is generally poor,
but may be improved by early diagnosis with risk
stratification and proper management.
Case report
A 43 year-old female patient was admitted to
our unit with shortness of breath. She had dyspnea,
decreased exercise tolerance and palpitations of two
years’ duration. On admission, the patient was in
a good hemodynamic condition and in New York
Heart Association (NYHA) class II. Physical exami-
nation and laboratory tests revealed no abnormali-
ty. The electrocardiogram (ECG) showed normal
sinus rhythm with findings of LV hypertrophy.
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Echocardiography revealed LV dilatation (end-
-diastolic volume 173 mL), normal wall thickening
(both interventricular septum and posterior wall
were 8.5 mm), widespread LV hypokinesis with an
ejection fraction (LVEF) of 33%, restrictive type
diastolic filling pattern with mitral E/E’ ratio of 17,
moderate mitral regurgitation and pulmonary hy-
pertension (estimated systolic pulmonary artery
pressure: 45 mm Hg). Heavy trabeculations were
noted at the LV apical and lateral walls (Fig. 1).
Coronary angiography revealed normal coronary
arteries. Basal and contrast-enhanced cardiac mag-
netic resonance imaging (MRI) confirmed the pres-
ence of trabeculation and intertrabecular recesses,
with a two-layered structure of the endocardium
with an increased noncompacted to compacted ra-
tio (> 2.0) in the LV lateral wall, as well as global
hypokinesis and an increased LV volume, which
were all compatible with LVNC (Fig. 2).
The patient received aspirin 100 mg/day,
carvedilol 12.5 mg/day, and spironolactone 25 mg/
/day. She was considered for a possible ICD implan-
tation for primary prevention of SCD. The 24-hour
ECG Holter monitoring showed sinus bradycardia,
frequent episodes of ventricular bigeminy, and non-
-sustained ventricular tachycardia (VT). During
hospitalization, several episodes of asymptomatic
VT was observed on ECG monitoring. Considering
LVNC with decreased LVEF, nonsustained VT epi-
sodes and a family history of SCD, the patient was
a class I (evidence level B) according to the recent
guidelines for the management of patients with VA
and the prevention of SCD [5]. A single-chamber
ICD device (Maximo VR, Medtronic, Inc., Minne-
apolis, MN, USA) was implanted. The patient was
discharged without complications. Follow-up at six
months revealed no episodes of VT or syncope.
Discussion
LVNC is characterized by electrical abnorma-
lities including low voltage and scar areas, mainly
related to the presence and extent of myocardial
fibrosis rather than noncompacted myocardium [6].
In previous studies, ventricular tachyarrhythmias
have been reported in up to 47% of symptomatic
patients referred to a tertiary referral center, and
SCD reported in 13–18% of (mostly adult) patients
with LVNC [2, 7]. Such findings support the hy-
pothesis that noncompacted ventricular myocar-
dium may be a highly arrhythmogenic substrate
with a high recurrence rate in patients with a his-
tory of syncope and/or VT. Although all the three
main mechanisms responsible for arrhythmoge-
nesis (re-entry, triggered activity, and abnormal
automaticity) have been implicated in the genesis
of VA in patients with LVNC, myocardial macrore-
entry is probably the responsible mechanism. The
histological examination of patients with LVNC
shows evidence of continuity between the LV en-
docardium and the deep intertrabecular recesses
that may be suitable for substrate formation for
propagation of various reentrant circuits subjacent
to scar [7].
Figure 2. Cardiac magnetic resonance imaging end-
-diastolic short axis bright blood B-TFE sequence cine
images showing a markedly dilated left ventricle with
compacted myocardium (*) and areas of substantial
trabeculations (ie noncompacted myocardium) in the
anterior, septum and lateral wall (arrows); LV — left
ventricle; RV — right ventricle.
Figure 1. Heavy trabeculation of the left ventricle’s apical
and lateral walls; LA — left atrium; RA — right atrium;
LV — left ventricle.
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Although a high incidence of VT and SCD is
expected, little consensus exists on the treatment
of ventricular and supraventricular arrhythmias in
this cohort of patients. What is suggested at the
moment is that patients with LVNC should be close-
ly monitored by conventional cardiologic diagnos-
tic tools, with appropriate measures taken only if
indicated [8]. Although implantation of ICD is
a treatment option, its superiority over medical
therapy is still being debated and there is limited
data on long-term follow-up [4]. While some authors
favor ICD implantation to prevent SCD, others pre-
fer choosing the patient at highest risk. Kobza et
al. [9] suggested that ICD therapy might be effec-
tive for primary and secondary prevention in these
patients. They conducted a retrospective study on
12 patients with LVNC, who underwent ICD im-
plantation for secondary and primary prevention.
During a median follow-up of 36 months, five pa-
tients received appropriate ICD therapy. Similar-
ly, Duru et al. [10] reported a patient with LVNC
and ICD who had developed numerous different VT
episodes that were appropriately treated by the
device. Celiker et al. [11] reported a six year-old
child with LVNC and ICD who had three ventricu-
lar fibrillation episodes which were treated with
appropriate shocks during a follow-up of 16 months.
On the other hand, Stanton et al. [12] analyzed the
follow-up data of 30 patients with LVNC and report-
ed no appropriate therapies during a mean follow-
-up of 2.5 years among the 11 LVNC patients who
were implanted with ICD. They also did not find any
difference in mortality between patients with LVNC
and patients with dilated cardiomyopathy during
follow-up. They concluded that deaths in the LVNC
group (three patients out of 30) were observed only
in patients with decreased LVEF, suggesting that
ICD therapy might be reserved for this subgroup.
While the necessity of ICD implantation is be-
ing argued, nearly all reports have pointed out that
supraventricular tachyarrhythmias, especially new-
onset atrial fibrillation, might lead to inappropriate
ICD discharges [12]. Patients with LVNC may de-
velop supraventricular tachyarrhythmias; atrial fi-
brillation had been reported in up to 29% of patients
[2, 7]. Kobza et al. [9] reported that intermittent
supraventricular tachyarrhythmias were observed
in 66% of patients, and that patients with supraven-
tricular tachyarrhythmias were more prone to in-
appropriate ICD shocks. Therefore, they suggest-
ed devices with reliable detection enhancements be
considered in these patients.
It is extremely hard to establish a correct strati-
fication of the arrhythmogenic risk in these patients.
The LV systolic dysfunction assessed either by
echocardiography or cardiac MRI and detection of
sustained VT during 24-hour Holter monitoring
might be useful in determining the risk [13]. Pro-
longed monitoring by means of a loop recorder
might also provide better information [14]. The
role of electrophysiological study (EPS) to deter-
mine the risk for VA and SCD is not well estab-
lished in LVNC. Kobza et al. [9] reported that the
three patients in whom a sustained VT had been
induced during EPS received appropriate ICD
shocks. However, they stated that the number of
patients in their study was too small to allow them
to devise parameters that would predict risk for
SCD. Some authors prefer to implant an ICD even
if no sustained VT or fibrillation is observed dur-
ing EPS [14]. A recent study pointed out that
symptoms of heart failure, a history of sustained
VT or an enlarged left atrium were associated with
an unstable course and more severe prognosis
[15]. Oechslin et al. [7] reported that certain clini-
cal characteristics were more frequently observed
in non-survivors compared with survivors with
LVNC, including higher LV end-diastolic diame-
ter on presentation, NYHA class III–IV, permanent
or persistent atrial fibrillation, and bundle branch
block. Patients with these high risk features might
be candidates for early, aggressive intervention,
including consideration of ICD implantation and
evaluation for transplantation.
In our case, we decided to perform ICD implan-
tation on the basis of the young age of our patient,
the family history of SCD, the LV systolic dysfunc-
tion and the documentation of nonsustained VT on
Holter monitoring.
Conclusions
Life-threatening VA may occur in patients with
LVNC. Its low prevalence and the limited data avail-
able in the literature do not allow us to make a firm
conclusion on the prognosis of these patients. The
best therapeutic decision should be based on the
patient’s own clinical features and the physician’s
judgement. We would currently recommend that
a patient with LVNC be implanted with an ICD in
cases of aborted cardiac arrest, sustained VT, syn-
cope related to VA, family history of SCD, or se-
verely impaired LVEF.
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